Promising Perioperative Regimen for Cisplatin-Eligible MIBC

CHICAGO 2026

Genitourinary Cancer

SAKK 06/19: Intravesical recombinant BCG plus perioperative chemoimmunotherapy shows promising efficacy in patients with MIBC

ESMO 2025

Genitourinary Cancer

LBA2: KEYNOTE-905: Perioperative enfortumab vedotin plus pembrolizumab emerges as a potential new standard of care for cisplatin-ineligible MIBC

Genitourinary Cancer

Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle-Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab-Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials

Int J Cancer

Mangold MH, Baumann G, Wieland VLS, Carl N, Renner LV, Studier-Fischer A, Menold H, Zschäbitz S, Wessels F, Westhoff N, Michel MS, Kowalewski KF, Haney-Aubert CM

doi: 10.1002/ijc.70525

Genitourinary Cancer

Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomy

BJU Int

Fazili A, Jazayeri SB, Rose KM, Guske C, Wen L, Durant A, Prunty M, Bukavina L, Tyson MD, Grass GD, Xu H, Spiess PE, Gilbert SM, Sexton WJ, Zemp L, Pessoa RR, Poch M, Lerner SP, Li R

doi: 10.1111/bju.16895

SPECIAL REPORT

Genitourinary Cancer

Insights from the EMBARK Trial: Identifying Eligible Patients for Optimized Outcomes

Gastrointestinal Cancer

Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials

Cancer Treat Rev

Zhao JJ, Yi Ng KY, Sundar R, Klempner SJ

doi: 10.1016/j.ctrv.2025.103002

Genitourinary Cancer

Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase 2 Trial SAKK 06/19

J Clin Oncol

Cathomas R, Petrausch U, Hayoz S, Spahn M, Bubendorf L, Schäuble K, Strebel RT, Niederberger P, Stenner F, Hirschi A, Vogl U, Lorch A, Tsantoulis P, Aeppli S, Erdmann A, Maranta AF, Fankhauser C, Hötker AM, Pausch AM, Herzig P, Le Gall V, Zippelius A, Chiquet S, Rothschild SI, Rentsch CA

doi: 10.1200/JCO-26-00845

WCLC 2025

Lung, Respiratory and Thoracic Cancer

KEYNOTE-671: Perioperative pembrolizumab improves efficacy outcomes regardless of nodal status in patients with early-stage NSCLC

ESMO 2025

Genitourinary Cancer

Related content

SAKK 06/19: Intravesical recombinant BCG plus perioperative chemoimmunotherapy shows promising efficacy in patients with MIBC

LBA2: KEYNOTE-905: Perioperative enfortumab vedotin plus pembrolizumab emerges as a potential new standard of care for cisplatin-ineligible MIBC

Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle-Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab-Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials

Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomy

Insights from the EMBARK Trial: Identifying Eligible Patients for Optimized Outcomes

Checkpoint inhibitor benefit in perioperative gastro-esophageal cancer: A meta-analysis of phase III trials

Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single-Arm Phase 2 Trial SAKK 06/19

KEYNOTE-671: Perioperative pembrolizumab improves efficacy outcomes regardless of nodal status in patients with early-stage NSCLC

TROPION-PanTumor03: Dato-DXd plus rilvegostomig shows promising activity in patients with advanced urothelial cancer